AKBA

Auryxia (ferric citrate)

control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis AND treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

Stage (next event)

Expected Date

Quarterly Sales (Approved)

February 24, 2021

Catalyst Info & Data Links

TITLE: Auryxia (ferric citrate) for control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis AND treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis Quarterly Sales (Approved)


WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 24, 2020 (Est)


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION 

  • Upon swallowing AURYXIA, ferric iron is converted to ferrous iron by the enzyme ferric reductase in the gastrointestinal tract, where the molecules are absorbed in the same highly regulated physiological pathway as dietary iron.2,3,5,6 In the bloodstream, ferrous iron is oxidized back to ferric iron, which binds to transferrin, an iron transfer protein that transports iron to the bone marrow for incorporation into hemoglobin for RBC production.

  • Source 

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon